The FDA has expanded the indication of once-weekly basal insulin icodec-abae to include children and adolescents aged 10 years and older with type 2 diabetes.
The conversion from accelerated to traditional approval updates the tumor mutational burden threshold from 10 to 13 mutations ...
Mean percentage of time that CGM-measured glucose level was in range of 70 to 180mg/dL was 21 percentage points higher with CGM ...
Strong recommendations include distinguishing bothersome from nonbothersome tinnitus, asking about risks for self-harm.
HealthDay News — Antipsychotic treatment initiation is associated with rapid increases in hemoglobin A1c (HbA1c) and weight, according to a study published in the November issue of The Lancet ...
The new 150mg oral pellet formulation provides a capsule-free prophylactic option for adults and adolescents with hereditary ...
The investigational vaccine targets pathological amyloid-beta to lower brain amyloid in patients with preclinical Alzheimer ...
Accelerated approval is supported by 34-week interim data from the phase 3 I CAN trial showing a statistically significant 43% placebo-adjusted reduction in proteinuria.
Enzyme-inducing ASDs increase risk for incident osteoporosis or osteopenia, but few patients receive vitamin D supplementation.
Patients with baseline viral suppression maintained viral suppression, while those without achieved viral suppression by 13 ...
A review of 5 investigational therapies with target action dates in November 2026, spanning neurology, gastroenterology, and oncology.
The FDA has approved Hibsago (bepirovirsen) as an add-on antisense oligonucleotide therapy to help noncirrhotic adults with chronic hepatitis B achieve functional cure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results